Luis Pena - Dermira Insider

DERM -- USA Stock  

USD 10.53  0.20  1.86%

Co-Founder and Executive VP of Product Devel.
Mr. Luis C. Pena is CoFounder, Chief Development Officer of the Company. He is a cofounder and has served as our chief development officer since February 2016, after previously serving as our executive vice president of product development from July 2013 to February 2016 and our vice president of product development from June 2011 to July 2013. From November 2010 to June 2011, Mr. Pea served as a consultant to our company. Mr. Pea served as Vice President, Head of Global Prescription Development of Stiefel, a GSK company, from January 2010 to March 2011 and, from January 2007 to December 2009, Mr. Pea served as Senior Vice President Portfolio Planning and Management of Stiefel, prior to its acquisition by GlaxoSmithKline LLC. From 2005 to 2007, Mr. Pea served as Vice President of Portfolio Planning and Management of Connetics. From 2001 to 2005, Mr. Pea served as Vice President of Product Development of Nuvelo, Inc., a biopharmaceutical company. Previously, Mr. Pea served as Senior Director of Project Planning and Management for Theravance, Incorporated, a pharmaceutical company, and held various positions in manufacturing, research and development at Genentech. Mr. Pea currently serves as an advisor to the SPARK program for the Stanford University School of Medicine where he was an advisor since 2012
Age: 54  Founder Since 2016      
650-421-7200  http://www.dermira.com
Pe?a holds a B.S. in biochemistry from San Francisco State University.

Luis Pena Latest Insider Activity

Luis Pena over two months ago via Macroaxis 
Dermira exotic insider transaction detected

Management Efficiency

The company has return on total asset (ROA) of (25.67) % which means that it has lost $25.67 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (124.96) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 279.85 M in liabilities with Debt to Equity (D/E) ratio of 218.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dermira has Current Ratio of 5.07 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Dermira operates under Biotechnology classification in USA and traded on NASDAQ. It employs 162 people.Dermira (DERM) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 162 people. Dermira is listed under Pharmaceutical Products category by Fama And French industry classification.

Dermira Leadership Team

Jake Nunn, Director, CFA
Frederick Craves, Director
William Young, Chairman
Ian Clements, Executive
Lori LyonsWilliams, Executive, MBA
Christopher Griffith, Founder, MBA
Matthew Fust, Director, MBA
David Cohen, Director
Kathleen Sebelius, Director
Mark McDade, Director, MBA
Emmanuel Caeymaex, Director
Christopher Horan, Executive
William Ringo, Director, MBA
Luis Pena, Founder
Thomas Wiggans, Chairman, MBA
Eugene Bauer, Director
Andrew Guggenhime, COO, MBA

Stock Performance Indicators

Did you try this?

Run Fundamentals Matrix Now
   

Fundamentals Matrix

View fundamentals matrix and analyze how accounts are interrelated and interconnected with each other
All  Next Launch Fundamentals Matrix

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Dermira and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.